StockNews.AI
CMRX
StockNews.AI
161 days

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, WBA, BLUE on Behalf of Shareholders

1. CMRX plans to be sold to Jazz Pharmaceuticals for $8.55 per share. 2. Halper Sadeh LLC investigates potential violations related to this transaction. 3. Shareholders may seek increased consideration or additional disclosures. 4. Legal options are being provided for concerned shareholders.

4m saved
Insight
Article

FAQ

Why Bullish?

The set price of $8.55 signals potential shareholder gains, attracting buyers. Past acquisitions often lead to short-term price increases, similar to CMRX's current situation.

How important is it?

The investigation highlights potential volatility around the acquisition, directly impacting shareholder value. Positive or negative outcomes will significantly affect CMRX's stock price.

Why Short Term?

The news may influence market activity immediately following the announcement. Historical trends indicate that acquisition announcements prompt immediate price movements.

Related Companies

JAZZWBABLUE
NEW YORK, March 11, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chimerix, Inc. (NASDAQ: CMRX)'s sale to Jazz Pharmaceuticals plc for $8.55 per share in cash. If you are a Chimerix shareholder, click here to learn more about your rights and options. Walgreens Boots Alliance (NASDAQ: WBA)'s sale to Sycamore Partners. Under the terms of the proposed transaction, Walgreens shareholders will receive $11.45 per share in cash at closing and one non-transferable right to receive up to $3.00 in cash per Walgreens share from the future monetization of Walgreens' debt and equity interests in VillageMD. If you are a Walgreens shareholder, click here to learn more about your rights and options. bluebird bio, Inc. (NASDAQ: BLUE)'s sale to Carlyle Group and SK Capital Partners, LP. Per the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent value right per share worth $6.84 in cash per contingent value right if bluebird's current product portfolio achieves $600 million in net sales in any trailing 12-month period prior to or ending on December 31, 2027. If you are a bluebird shareholder, click here to learn more about your legal rights and options. Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected]. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information:Halper Sadeh LLCDaniel Sadeh, Esq.Zachary Halper, Esq.(212) 763-0060[email protected][email protected] https://www.halpersadeh.com SOURCE Halper Sadeh LLP

Related News